Levosalbutamol in the treatment of asthma

Bibliography

• WIELAND K, ZUURMOND HM, KRASEL C, IJZERMAN AP, LOHSE MJ: Involvement of Asn-293 in stereospecific agonist recognition and in activation of the β2-adrenergic receptor. Proc. Natl. Acad. Sci. USA (1996) 93:9276-9281.
   PubMed Web of Science ®Google Scholar
• PENN RB, FRIELLE T, MCCULLOUGH JR, ABERG G, BENOVIC JL: Comparison of R-, S-, and RS-albuterol interaction with human β1- and β2-adrenergic receptors. Clin. Rev. Allergy Immunol. (1996) 14:37-45.
   PubMed Web of Science ®Google Scholar
• COCKCROFT DW, SWYSTUN VA: Effect of single doses of S-salbutamol, R-salbutamol, racemic salbutamol, and placebo on the airway response to methacholine. Thorax (1997) 52:845-848.
   PubMed Web of Science ®Google Scholar
• IND PW: Salbutamol enantiomers: early clinical evidence in humans. Thorax (1997) 52:839-840.
   PubMed Web of Science ®Google Scholar
• HOITING BH, MEURS H, SCHUILING M, KUIPERS R, ELZINGA CR, ZAAGSMA J: Modulation of agonist-induced phosphoinositide metabolism, Ca2+ signalling and contraction of airway smooth muscle by cyclic AMP-dependent mechanisms. Br. J. Pharmacol. (1996) 117:419-426.
   PubMed Web of Science ®Google Scholar
• MITRA S, UGUR M, UGUR O, GOODMAN HM, MCCULLOUGH JR, YAMAGUCHI H: (S)-Albuterol increases intracellular free calcium by muscarinic receptor activation and a phospholipase C-dependent mechanism in airway smooth muscle. Mol. Pharmacol. (1998) 53:347-354.
   PubMed Web of Science ®Google Scholar
• AGRAWAL DK, ARIYARATHNA K, KELBE PW: (S)-Albuterol activates pro-constrictory and pro-inflammatory pathways in human bronchial smooth muscle cells. J. Allergy Clin. Immunol. (2004) 113:503-510.
   PubMed Web of Science ®Google Scholar
• VOLCHECK G, GLEICH G, KITA H: Pro- and anti-inflammatory effects of β-adrenergic agonists on eosinophil response to IL-5. J. Allergy Clin. Immunol. (1998) 101:S35.
   Web of Science ®Google Scholar
• CHO SH, HARTLEROAD JY, OH CK: (S)-Albuterol increases the production of histamine and IL-4 in mast cells. Int. Arch. Allergy Immunol. (2001) 124:478-484.
   PubMed Web of Science ®Google Scholar
• BARAMKI D, KOESTER J, ANDERSON AJ, BORISH L: Modulation of T-cell function by (R)- and (S)-isomers of albuterol: anti-inflammatory influences of (R)-isomers are negated in the presence of the (S)-isomer. J. Allergy Clin. Immunol. (2002) 109:449-454.
   PubMed Web of Science ®Google Scholar
• SAUNDERS MA, MITCHELL JA, SELDON PM et al.: Release of granulocyte-macrophage colony stimulating factor by human cultured airway smooth muscle cells: suppression by dexamethasone. Br. J. Pharmacol. (1997) 120:545-546.
   PubMed Web of Science ®Google Scholar
• ENDO T, UCHIDA Y, NOMURA A et al.: Activated eosinophils stimulate endothelin-1 release from airway epithelial cells by direct adherence via adhesion molecules. Pulm. Pharmacol. Ther. (1997) 10:81-87.
   PubMed Web of Science ®Google Scholar
• HALLSWORTH MP, SOH CP, TWORT CH, LEE TH, HIRST SJ: Cultured human airway smooth muscle cells stimulated by interleukin-1β enhance eosinophil survival. Am. J. Respir. Cell Mol. Biol. (1998) 19:910-919.
   PubMed Web of Science ®Google Scholar
• AMEREDES B, CALHOUN W: Modulation of GM-CSF release by enantiomers of β2-agonists in human airway smooth muscle. J. Allergy Clin. Immunol. (2005) 116:65-72.
   PubMed Web of Science ®Google Scholar
• GIBSON B, FRIDAY S, WATKINS S, AMEREDES B, CALHOUN W: Effects of dexamethasone and β-agonist enantiomers on glucocorticoid receptor translocaton. J. Allergy Clin. Immunol. (2005) 115:S59.
   Google Scholar
• KEIR S, PAGE C, SPINA D: Bronchial hyperresponsiveness induced by chronic treatment with albuterol: role of sensory nerves. J. Allergy Clin. Immunol. (2002) 110:388-394.
   PubMed Web of Science ®Google Scholar
• AGRAWAL D, CLARK K, TOWNLEY R: Dfferential effects of albuterol enantiomers on pulmonary functions and bronchoalveolar lavage (BAL) eosinophilia. Am. J. Respir. Crit. Care Med. (2000) 161:A191.
   Google Scholar
• PETERSON B, MILLER E: Effects of enantiomers of albuterol on lung epithelial permeability. Am. J. Respir. Crit. Care Med. (2000) 161:A416.
   Google Scholar
• RAMSAY CM, COWAN J, FLANNERY E, MCLACHLAN C, TAYLOR DR: Bronchoprotective and bronchodilator effects of single doses of (S)-salbutamol, (R)-salbutamol and racemic salbutamol in patients with bronchial asthma. Eur. J. Clin. Pharmacol. (1999) 55:353-359.
   PubMed Web of Science ®Google Scholar
• NELSON HS, BENSCH G, PLESKOW WW et al.: Improved bronchodilation with levalbuterol compared with racemic albuterol in patients with asthma. J. Allergy Clin. Immunol. (1998) 102:943-952.
   PubMed Web of Science ®Google Scholar
• PLESKOW WW, NELSON HS, SCHAEFER K, CLAUS R, ROACH JM: Pairwise comparison of levalbuterol versus racemic albuterol in the treatment of moderate-to-severe asthma. Allergy Asthma Proc. (2004) 25:429-436.
   PubMed Web of Science ®Google Scholar
• LOTVALL J, PALMQVIST M, ARVIDSSON P, MALONEY A, VENTRESCA GP, WARD J: The therapeutic ratio of R-albuterol is comparable with that of RS-albuterol in asthmatic patients. J. Allergy Clin. Immunol. (2001) 108:726-731.
   PubMed Web of Science ®Google Scholar
• MILGROM H, SKONER D, BENSCH G, KIM K, CLAUS R, BAUMGARTNER R: Reply. J. Allergy Clin. Immunol. (2002) 110:325-328.
   PubMedGoogle Scholar
• DOSE RESPONSE INFORMATION TO SUPPORT DRUG REGISTRATION: In: International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (1994). (Available at http://www.ich.org/cache/ compo/475-272-1.html).
   Google Scholar
• NOWAK R, EMERMAN C, CLAUS R et al.: Levalbuterol (LEV) versus racemic albuterol (RAC) in acute severe asthma: a prospective trial. Am. J. Emerg. Med. (2004) 22(1):29-36.
   PubMed Web of Science ®Google Scholar
• NOWAK R, EMERMAN C, HANRAHAN JP et al.: A comparison of levalbuterol with racemic albuterol in the treatment of acute severe asthma exacerbations in adults. Am. J. Emerg. Med. (2006) 24:259-267.
   PubMed Web of Science ®Google Scholar
• TRUITT T, WITKO J, HALPERN M: Levalbuterol compared to racemic albuterol: efficacy and outcomes in patients hospitalized with COPD or asthma. Chest (2003) 123:128-135.
   PubMed Web of Science ®Google Scholar
• HAIDER D: Levalbuterol affords superior health and cost benefit over racemic albuterol in the emergency department. Respir. Care (2001) 46:1081.
   Google Scholar
• GAWCHIK SM, SACCAR CL, NOONAN M, REASNER DS, DEGRAW SS: The safety and efficacy of nebulized levalbuterol compared with racemic albuterol and placebo in the treatment of asthma in pediatric patients. J. Allergy Clin. Immunol. (1999) 103:615-621.
   PubMed Web of Science ®Google Scholar
• MILGROM H, SKONER DP, BENSCH G, KIM KT, CLAUS R, BAUMGARTNER RA: Low-dose levalbuterol in children with asthma: safety and efficacy in comparison with placebo and racemic albuterol. J. Allergy Clin. Immunol. (2001) 108:938-945.
   PubMed Web of Science ®Google Scholar
• CARL JC, MYERS TR, KIRCHNER HL, KERCSMAR CM: Comparison of racemic albuterol and levalbuterol for treatment of acute asthma. J. Pediatr. (2003) 143:731-736.
   PubMed Web of Science ®Google Scholar
• SKONER DP, GREOS LS, KIM KT, ROACH JM, PARSEY M, BAUMGARTNER RA: Evaluation of the safety and efficacy of levalbuterol in 2-5-year-old patients with asthma. Pediatr. Pulmonol. (2005) 40:477-486.
   PubMed Web of Science ®Google Scholar
• HARTMAN AP, WILSON AA, WILSON HM, ABERG G, FALANY CN, WALLE T: Enantioselective sulfation of β2-receptor agonists by the human intestine and the recombinant M-form phenolsulfotransferase. Chirality (1998) 10:800-803.
   PubMed Web of Science ®Google Scholar
• WARD JK, DOW J, DALLOW N, EYNOTT P, MILLERI S, VENTRESCA GP: Enantiomeric disposition of inhaled, intravenous and oral racemic-salbutamol in man-no evidence of enantioselective lung metabolism. Br. J. Clin. Pharmacol. (2000) 49:15-22.
   PubMed Web of Science ®Google Scholar
• MAIER G, RUBINO C, HSU R, GRASELA T, BAUMGARTNER R: Population pharmacokinetics of (R)-albuterol and (S)-albuterol in pediatric patients aged 4 to 11 years with asthma. (2005).
   Google Scholar
• SCHMEKEL B, RYDBERG I, NORLANDER B, SJOSWARD KN, AHLNER J, ANDERSSON RG: Stereoselective pharmacokinetics of S-salbutamol after administration of the racemate in healthy volunteers. Eur. Respir. J. (1999) 13:1230-1235.
   PubMed Web of Science ®Google Scholar
• DHAND R, GOODE M, REID R, FINK JB, FAHEY PJ, TOBIN MJ: Preferential pulmonary retention of (S)-albuterol after inhalation of racemic albuterol. Am. J. Respir. Crit. Care Med. (1999) 160:1136-1141.
   PubMed Web of Science ®Google Scholar
• THOMPSON M, WISE S, RODENBERG H: A preliminary comparison of levalbuterol and albuterol in prehospital care. J. Emerg. Med. (2004) 26:271-277.
   PubMed Web of Science ®Google Scholar
• HARDASMALANI MD, DEBARI V, BITHONEY WG, GOLD N: Levalbuterol versus racemic albuterol in the treatment of acute exacerbation of asthma in children. Pediatr. Emerg. Care (2005) 21:415-419.
   PubMed Web of Science ®Google Scholar
• QURESHI F, ZARITSKY A, WELCH C, MEADOWS T, BURKE BL: Clinical efficacy of racemic albuterol versus levalbuterol for the treatment of acute pediatric asthma. Ann. Emerg. Med. (2005) 46:29-36.
   PubMed Web of Science ®Google Scholar
• RALSTON ME, EUWEMA MS, KNECHT KR, ZIOLKOWSKI TJ, COAKLEY TA, CLINE SM: Comparison of levalbuterol and racemic albuterol combined with ipratropium bromide in acute pediatric asthma: a randomized controlled trial. J. Emerg. Med. (2005) 29:29-35.
   PubMed Web of Science ®Google Scholar
• BERGER WE, AMES DE, HARRISON D: A patient satisfaction survey comparing levalbuterol with racemic albuterol in children. Allergy Asthma Proc. (2004) 25:437-444.
   PubMed Web of Science ®Google Scholar
• BERGER WE: Levalbuterol: pharmacologic properties and use in the treatment of pediatric and adult asthma. Ann. Allergy Asthma Immunol (2003) 90:583-591.
   PubMed Web of Science ®Google Scholar